An anti-EGFR antibody conjugated to MMAF, Depatuxizumab-mafodotin (Depatux-M), was administered to patients with glioblastoma (GBM) receiving standard treatment with radiotherapy plus temozolomide [37]. The gene discussed is EGFR; the disease is glioblastoma.